zoeti spun lead global manufactur medic vaccin
livestock revenu companion anim revenu
better expect result exemplifi strength zoetiss
busi model divers also consist out-performance
leadership ceo juan ramon alaix retir end year
pass torch ceo-elect kristin peck given ms peck experi
industri think great job drive consist growth
expand compani lead innov posit area like diagnost
precis farm leverag data digit technolog indic
expect fda approv simparica trio late launch
shortli first time compani provid expect trio
revenu given upcom posit catalyst zoeti
maintain buy rate rais price target
nutshel adjust ep higher consensu
higher estim revenu increas
report basi in-lin street estim
fx bp headwind revenu increas
oper cc basi organ cc revenu grew driven price
volum companion anim oper revenu growth
driven growth intern growth livestock
sale decreas oper driven declin
 declin intern gross margin increas bp
bp higher project driven
fx product mix price offset lower margin legaci abaxi sale
simparica trio expect set earn call manag
state expect fda approv simparica trio late
subsequ plan launch follow trio launch
europ canadian earlier year assum approv follow
timelin expect simparica trio gener increment sale
major revenu come importantli
target includ expect cannib expect trio puppi
claim dog week older differ age first use
simparica month zoeti continu expand field sale forc
support companion anim busi includ diagnost launch
trio next year continu believ one two year first-
mover advantag broad-spectrum parasiticid lead
meaning growth market share gain
page
period except per share revenueadj epsrevenueadj epsrevenueadj epsrevenueadj previou revis compani data factset estim craig-hallum capit group llc
companion anim develop activ encourag file
eu new monoclon antibodi treatment osteoarthrit pain
 one cat one dog expect launch product
approv believ felin pain treatment market blue
ocean could worth dog pain market
estim valu global
revenu increas oper driven growth
growth intern product sale growth
driven zoetiss parasiticid product proheart revoluion
simparica well apoquel cytopoint contribut abaxi
growth attribut increas sale apoquel
cytopoint contribut abaxi simparica stronghold
abaxi revenu increas oper
apoquel sale increas y/i
cytopoint sale increas y/i
simparica revenu increas y/i driven
 intern market
livestock growth weak due african swine fever soft cattl
market livestock oper growth declin global
 sale decreas intern livestock revenu decreas
declin attribut continu weak
dairi beef cattl market well time promot activ
swine partial off-set growth poultri product driven increas
sale antibiot altern medic feed addit lower
intern livestock sale driven continu impact african
swine fever china part asia lesser extent partial
off-set growth cattl poultri product cattl growth driven
favor market condit key geographi like mexico
canada neg impact unfavor y/i comparison
brazil due nation truck strike push sale
poultri product sale driven key market like china australia
page
varianc varianc except per share c-h estimate con actualto c-h estimate c-h estimate revenu growth primarili driven strong companion anim growth partial off-set byy/i livestock relat weak beef dairi market companion oper growth driven parasiticid portfolio proheart revolut y/i franchis growth key dermatolog product contribut abaxi sale declin due continu weak beef dairi cattl well timingy/i promot activ swine growth poultri driven antibiot altern revenu increaesd oper y/i basi y/i oper companion companion anim sale grew oper driven growth key dermatolog portfolio y/i abaxi acquisit parasiticid includ simparica stronghold plu oper livestock sale declin oper due on-going impact african swine fever chinay/i part asia offset growth cattl poultri product saw favorableoper market condit mexico canada neg y/i comparison brazil contract revenu grew oper basi organ growth fx impact y/i abaxi ad growth price contribut volum ad includ oper dermatolog product new product in-lin product sourc compani data factset estim craig-hallum capit group llc
geograph revenu detail oper cc growth strongest
mexico japan canada brazil
due tough y/i comparison relat nation truck
strike push greater sale continu expect
impact african swine fever compani expect export pork
protein increas region oper
growth china remain pressur due asf companion anim
product sale continu grow significantli attribut
higher sale parasiticid vaccin apoquel driven field forc
expans increas effect companion anim sale brazil
also strong partial off-set declin livestock
growth mexico remain strong across board livestock sale
companion anim product sale driven growth
legaci abaxi product parasiticid vaccin
revenu speci continu reflect strong growth companion anim
product sale dog cat percent total increas
year ago cattl weak sale cattl product declin
total revenu swine revenu
poultri account total revenu also
saw slight increas equin sale attribut platinum perform
guidanc increas revenu guidanc narrow
organ oper growth increas modestli also
increas adjust ep guidanc rais mid-point
rang think guidanc rais reflect strong companion
anim growth partial off-set weaker livestock growth
zoeti inc page
otherothertot million australiabrazilcanadachinafr germani italyjapanmexicospainuk compani report craig-hallum capit grouprev
increas price target base ev/ebitda multipl
ebitda estim project net debt share
outstand price target also support appli price-to-earnings multipl
ep estim valuat support long-term discount cash flow
dcf valuat analysi use termin growth rate wacc
believ invest zoeti involv follow risk
increas restrict ban use antibiot use growth promot
livestock fda work phase-out use medic import antibacteri
anim feed growth promot chang produc behavior increas regul
could advers impact zoetiss antibacteri product sale
lead chang underli market demand product
chang util product relat protein consumpt chang
consum spend habit diet protein consumpt could advers effect
zoeti busi
infecti diseas outbreak variou infecti diseas avian flu swine flu
etc could lead cull herd reduct use product
cash pay busi therefor chang economi input cost commod
price could neg impact produc abil buy product
industri consolid increas competit continu consolid
anim health industri could lead increas competit result price pressur
could neg impact margin profit
foreign currenc fluctuat approxim zoeti busi deriv
outsid creat foreign currenc risk
zoeti inc page
zoeti guidancepreviousupd million except per share fy oper cost sale sg interest expens andoth tax rate adj dilut net signific item andacquisition-rel dilut compani data factset estim chlm estim
page
zoetiscraig-hallum capit groupincom statement mm except per share kevin ellich oper oper oper tax net incom attr non-controlling incom attribut ebitda analysi oper incom attribut non-controlling oper incom attribut compani report craig-hallum capit group llc estimatesnovemb requir disclosur
